European Commission HTA Proposals Should Mandate Comparative Trials, Says Germany
Executive Summary
Pharmaceutical companies should be obliged to carry out comparative trials, according to analysis from Germany’s Institute For Quality and Efficiency in Healthcare, IQWiG.
You may also be interested in...
Subgroups & Missing Data: The Problems Facing HTAs In Europe
The DIA Europe 2020 conference heard from regulators and health technology assessment bodies about the problems that can arise over poorly defined patient populations and a lack of comparator data when making reimbursement decisions.
German HTA Body Slams Lack Of 'Real Innovation'
Too many new drugs have the same mechanism of action, says Germany’s health technology appraisal institute, IQWiG.
Industry Demands Rethink Of German HTA Data Requirements
The pharmaceutical industry is calling for more flexible evidence requirements for health technology assessments in Germany after the country’s HTA body, IQWiG, claimed that too many new products entering the market lack additional benefit.